Abstract | Background: This systematic review aimed to compare body weight gain associated outcomes over time between dolutegravir (DTG)-based antiretroviral (ART) regimens to other ART regimens, to compare tenofovir alafenamide (TAF)-based regimens, and to evaluate the associated prognostic factors. Methods: Systematic searches of MEDLINE, Embase, and CENTRAL for RCTs and observational studies comparing ART regimens were conducted on 13 September 2021. Outcomes of interest included: change in body weight, body mass index (BMI), waist circumference; and risk of hyperglycaemia and diabetes. Network meta-analyses were conducted at 12, 24, 48, 96 and 144 weeks using two networks differentiated by 3rd agents and backbone agents. Findings: Interpretation: DTG-based regimens lead to larger average weight gains than some other ART regimens and TAF leads to larger average weight gains than all other backbone antiretrovirals. Further research is needed to better understand long-term outcomes and their relationship to other metabolic outcomes. Funding:
|
Authors | Steve Kanters, Francoise Renaud, Ajay Rangaraj, Kenneth Zhang, Eve Limbrick-Oldfield, Monica Hughes, Nathan Ford, Marco Vitoria |
Journal | EClinicalMedicine
(EClinicalMedicine)
Vol. 48
Pg. 101412
(Jun 2022)
ISSN: 2589-5370 [Electronic] England |
PMID | 35706487
(Publication Type: Journal Article)
|
Copyright | © 2022 The Authors. |